Fruquintinib plus TAS-102 shows activity in heavily pretreated metastatic colorectal cancer

◆ TRIAL DATA

A phase II trial of 50 patients who had failed at least two prior therapies found median progression-free survival of 6.07 months and overall survival of 14.10 months, with 68% experiencing grade 3 or higher treatment-related adverse events. (MedComm)